The metabolism and drug–drug interaction potential of the selective prostacyclin receptor agonist selexipag

A pharmacokinetic drug–drug interaction study between selexipag and midazolam, a CYP3A4 substrate, in healthy male subjects

(2017) Pierre-Eric Juif et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Selexipag Active Metabolite ACT-333679 Displays Strong Anticontractile and Antiremodeling Effects but Low β -Arrestin Recruitment and Desensitization Potential

(2017) John Gatfield et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Selexipag: A Review in Pulmonary Arterial Hypertension

(2016) Sean T. Duggan et al.   American Journal of Cardiovascular Drugs

Investigation of Potential Pharmacodynamic and Pharmacokinetic Interactions Between Selexipag and Warfarin in Healthy Male Subjects

(2016) Shirin Bruderer et al.   CLINICAL THERAPEUTICS

Absolute oral bioavailability of selexipag, a novel oral prostacyclin IP receptor agonist

(2016) Priska Kaufmann et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacokinetic drug evaluation of selexipag for the treatment of pulmonary arterial hypertension

(2016) Mayank Sardana et al.   Expert Opinion on Drug Metabolism & Toxicology

Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy

(2016) Elizabeth A Hardin et al.   Drug Design Development and Therapy

2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

(2015) Nazzareno Galiè et al.   EUROPEAN HEART JOURNAL

Bioequivalence of different dose-strength tablets of selexipag, a selective prostacyclin receptor agonist, in a multiple-dose up-titration study

(2015) Daniela Baldoni et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

The mechanistic basis of prostacyclin and its stable analogues in pulmonary arterial hypertension: Role of membrane versus nuclear receptors

(2015) Lucie H. Clapp et al.   PROSTAGLANDINS & OTHER LIPID MEDIATORS

The molecular targets of approved treatments for pulmonary arterial hypertension

(2015) Marc Humbert et al.   THORAX

Pharmacologic Therapy for Pulmonary Arterial Hypertension in Adults

(2014) Darren B. Taichman et al.   CHEST

Multiple-Dose Up-Titration Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Selexipag, an Orally Available Selective Prostacyclin Receptor Agonist, in Healthy Subjects

(2014) Shirin Bruderer et al.   PHARMACOLOGY

Updated Treatment Algorithm of Pulmonary Arterial Hypertension

(2013) Nazzareno Galiè et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Updated Clinical Classification of Pulmonary Hypertension

(2013) Gerald Simonneau et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Review of P-gp Inhibition Data in Recently Approved New Drug Applications: Utility of the Proposed [I1]/IC50and [I2]/IC50Criteria in the P-gp Decision Tree

(2012) Sheetal Agarwal et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Human carboxylesterases HCE1 and HCE2: Ontogenic expression, inter-individual variability and differential hydrolysis of oseltamivir, aspirin, deltamethrin and permethrin

(2008) Dongfang Yang et al.   BIOCHEMICAL PHARMACOLOGY

Drug–Drug Interactions Mediated Through P-Glycoprotein: Clinical Relevance and In Vitro–In Vivo Correlation Using Digoxin as a Probe Drug

(2008) KS Fenner et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS